{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003516877,0.001500574,0.0027321,0.0004966203,0.0004544389,0.001826034,0.0009719961,0.002822652,0.01914242],"category_scores_gemma":[0.004270334,0.0006795808,0.003729358,0.0004843982,0.0005838756,0.0008638684,0.0002916179,0.002682645,0.002968339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006777559,"about_ca_system_score_gemma":0.001489647,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007633024,"about_ca_topic_score_gemma":0.00180104,"domain_scores_codex":[0.9988682,0.0006351139,0.0001374578,0.0001494938,0.0001209794,0.00008879966],"domain_scores_gemma":[0.9980983,0.0008070579,0.0004794537,0.00009161072,0.0002125902,0.0003108552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8709019,0.004384201,0.0006938725,0.0226891,0.01091147,0.00009937903,0.0000808628,0.0005180157,0.00434561,0.0005940654,0.01495936,0.0698223],"study_design_scores_gemma":[0.9611006,0.02637937,0.001285437,0.0009804603,0.004395025,0.00004209,0.00002115631,0.0001926937,0.0004183818,0.0003199506,0.004840447,0.00002438702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4446293,0.3856553,0.006356975,0.02325095,0.01444381,0.05520126,0.029483,0.001176096,0.03980332],"genre_scores_gemma":[0.7966594,0.1074269,0.007601855,0.02034483,0.008347743,0.02551733,0.01070208,0.0001661373,0.02323378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01914242,"threshold_uncertainty_score":0.0640378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1294819005494149,"score_gpt":0.4061370170159111,"score_spread":0.2766551164664962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}